129 related articles for article (PubMed ID: 37161798)
1. Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.
Mascarenhas J; Nguyen H; Saunders A; Oliver L; Tomkinson H; Perry R; McBride A
Future Oncol; 2023 Apr; 19(11):763-773. PubMed ID: 37161798
[TBL] [Abstract][Full Text] [Related]
2. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
3. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
4. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.
Bose P; Kuykendall AT; Miller C; Kurtin S; Farina K; Harting DM; Mascarenhas JO; Mesa RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1091-1100. PubMed ID: 37163478
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
8. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
Breccia M; Baratè C; Benevolo G; Bonifacio M; Elli EM; Guglielmelli P; Maffioli M; Malato A; Mendicino F; Palumbo GA; Pugliese N; Rossi E; Rumi E; Sant'Antonio E; Ricco A; Tiribelli M; Palandri F
Ann Hematol; 2020 Jan; 99(1):65-72. PubMed ID: 31832751
[TBL] [Abstract][Full Text] [Related]
9. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
[TBL] [Abstract][Full Text] [Related]
10. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
12. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
13. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.
Breccia M; Palandri F; Guglielmelli P; Palumbo GA; Malato A; Mendicino F; Ricco A; Sant'Antonio E; Tiribelli M; Iurlo A
Curr Oncol; 2022 Jul; 29(7):4970-4980. PubMed ID: 35877255
[TBL] [Abstract][Full Text] [Related]
14. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
15. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
Passamonti F; Heidel FH; Parikh RC; Ajmera M; Tang D; Nadal JA; Davis KL; Abraham P
Future Oncol; 2022 Jun; 18(18):2217-2231. PubMed ID: 35388710
[No Abstract] [Full Text] [Related]
18. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan KM; Elmeshhadany AY; Shabila NP
Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
[TBL] [Abstract][Full Text] [Related]
20. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
